Used to address oncology care, this generic medicine slows the replication of abnormal cellular DNA to limit the progression of specific cell populations.
Designed to support neoplastic disease management to manage lymphocytic levels and alleviate tumor replication.
Mechanism of Action
Forms covalent cross-links with cellular DNA, disrupting replication and transcription to trigger programmed death in neoplastic cells.
Route of Administration
Oral
Onset Time
2–3 weeks
Duration
24 hours
Contraindications
Severe bone marrow suppression, Previous resistance to chlorambucil
Severe Adverse Events
Severe myelosuppression — requires immediate medical attention, Acute leukemia development — requires immediate medical attention, Pulmonary fibrosis — requires immediate medical attention
Common Side Effects
Nausea, Vomiting, Alopecia
Uncommon Side Effects
Myelosuppression, Skin rash, Fever
Drug Interactions
Live Vaccines
Pregnancy Safety Warnings
TGA Category D: High risk of fetal toxicity. Do not use in pregnancy. Breastfeeding: Contraindicated.
Age Restrictions
Approved for adults. Used in pediatric populations under strict protocols.
Information related to Leukeran is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
